{
    "nctId": "NCT06449027",
    "briefTitle": "Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.",
    "officialTitle": "A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer Subjects",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Observe the proportion of subjects whose E2 levels remain at postmenopausal levels between 4 and 48 weeks after treatment, to assess the Efficacy of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subject.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal female subjects aged 18 to 55 years old.\n* Histological or cytological confirmation of HR+\uff0cHER2- premenopausal breast cancer.\n* Subjects have any breast cancer surgery before informing, and no clinical residual local regional lesions were found after the surgery.\n* Life expectancy is not less than 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate function of major organs.\n\nExclusion Criteria:\n\n* History of evidence of distant metastatic lesions;\n* Subjects have the history of new adjuvant or adjuvant endocrine treatment for breast cancer ( Excluding subjects receiving tamoxifen citrate tablets treatment for less than 12 weeks before informing).\n* Active hepatitis B, hepatitis C or HIV in screening.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}